CYP19A1 and neutropenia: The aromatase inhibitors and ABE are continuously administered as single daily doses, FUL is a once-monthly intramuscular injection, and the dosing regimen of PAL and RIB involves a week off treatment every 21 days to minimize treatment-induced neutropenia [8].